• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Treatment for Lou Gehrig ' s Disease Shows Promise
A study of their therapy and clinical trials of other experimental treatments are offering glimmers of hope that paralysis from the disorder can be slowed.
Source: NYT Health - September 2, 2020 Category: Consumer Health News Authors: Pam Belluck Tags: Amyotrophic Lateral Sclerosis Clinical Trials Research Drugs (Pharmaceuticals) ALS Assn Food and Drug Administration National Institute of Neurological Disorders and Stroke New England Journal of Medicine Koroshetz, Walter J your-feed-he Source Type: news

US WorldMeds lands new FDA approval
Louisville-based pharmaceutical company US WorldMeds LLC received Food and Drug Administration approval for a new use of its drug Myobloc. Myobloc can now be used to treat sialorrhea, commonly known as drooling. It's a common and unfortunate symptom that follows many neurological disorders such as Parkinson's Disease, amyotrophic lateral sclerosis (ALS), cerebral palsy and stroke to name a few. "We are committed to helping patients who struggle with confidence due to their sialorrhea," US WorldMeds…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 28, 2019 Category: Pharmaceuticals Authors: Chris Larson Source Type: news

Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
This article discusses the preclinical pharmacology, pharmacokinetics, safety profile, clinical studies and drug interactions of edaravone (Radicava) in ALS. PMID: 29998226 [PubMed - in process]
Source: Drugs of Today - July 13, 2018 Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research

Neuroscience is the Next Oncology
by Michael D. Ehlers, MD, PhD Dr. Ehlers is with Biogen in Cambridge, Massachusetts. Innov Clin Neurosci. 2018;15(3–4):15–16 Funding: No funding was received for the preparation of this article. Disclosures: Dr. Ehlers is an employee and shareholder at Biogen Inc. in Cambridge, Massachusetts. Prominent and expensive failures in Alzheimer’s disease therapies have led to a contagious belief system in some parts of the biopharma industry that neuroscience is just too hard, too risky, and too uncertain. But, might this belief system itself be a residual bias of the past? Close inspection reveals all the signs of a coming...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Commentary Current Issue Source Type: research

How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?
Authors: Watanabe K, Tanaka M, Yuki S, Hirai M, Yamamoto Y Abstract Edaravone is a low-molecular-weight antioxidant drug targeting peroxyl radicals among many types of reactive oxygen species. Because of its amphiphilicity, it scavenges both lipid- and water-soluble peroxyl radicals by donating an electron to the radical. Thus, it inhibits the oxidation of lipids by scavenging chain-initiating water-soluble peroxyl radicals and chain-carrying lipid peroxyl radicals. In 2001, it was approved in Japan as a drug to treat acute-phase cerebral infarction, and then in 2015 it was approved for amyotrophic lateral sclerosi...
Source: Journal of Clinical Biochemistry and Nutrition - January 28, 2018 Category: Nutrition Tags: J Clin Biochem Nutr Source Type: research

Emerging Roles of Protein Kinases in Microglia-mediated Neuroinflammation.
Abstract Neuroinflammation is mediated by resident central nervous system glia, neurons, peripherally derived immune cells, blood-brain barrier, and inflammatory mediators secreted from these cells. Neuroinflammation has been implicated in stroke and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis. Protein kinases have been one of the most exploited therapeutic targets in the current pharmacological research, especially in studies on cancer and inflammation. To date, 32 small-molecule protein kinase inhibitors have been approved by ...
Source: Biochemical Pharmacology - July 3, 2017 Category: Drugs & Pharmacology Authors: Lee SH, Suk K Tags: Biochem Pharmacol Source Type: research